Correction: Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial (The Lancet Haematology (2017) 4(8) (e362–e373) (S2352302617301205)(10.1016/S2352-3026(17)30120-5));Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial

The Lancet Haematology

Volumn 4, Issue 8, 2017, Pages e362-e373

  Kim, Won Seog ^a   Buske, Christian ^b   Ogura, Michinori ^c   Jurczak, Wojciech ^d   Sancho, Juan Manuel ^e   Zhavrid, Edvard ^f   Kim, Jin Seok ^g   Hernández Rivas, José Ángel ^h   Prokharau, Aliaksandr ⁱ   Vasilica, Mariana ^j   Nagarkar, Rajinish ^k   Osmanov, Dzhelil ^l   Kwak, Larry W ^m   Lee, Sang Joon ⁿ   Lee, Sung Young ⁿ   Bae, Yun Ju ⁿ   Coiffier, Bertrand ^o  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c Tokai Central Hospital of the Mutual Aid Association of Public School Teachers   (Japan)

^d JAGIELLONIAN UNIVERSITY   (Poland)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^f SE Republican Scientific and Practical Center of Oncology Medical Radiology Named after NN Alexandrov   (Belarus)

^g Yonsei University College of Medicine   (South Korea)

^h HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

ⁱ Minsk City Hospital for Oncology   (Belarus)

^j FUNDENI CLINICAL INSTITUTE   (Romania)

^k Curie Manavata Cancer Centre   (India)

^l N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^m CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

ⁿ Celltrion Inc   (South Korea)

^o HOSPICES CIVILS DE LYON   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGINA PECTORIS; ANTIHISTAMINIC AGENT; BIOSIMILAR AGENT; CYCLOPHOSPHAMIDE; FISTULA; NEUTRALIZING ANTIBODY; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ANAPHYLAXIS; AREA UNDER THE CURVE; ARTICLE; CANCER STAGING; CAUSE OF DEATH; CHEMOLUMINESCENCE; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DEEP VEIN THROMBOSIS; DISEASE ASSESSMENT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; ENCEPHALITIS; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; ILEUS; LEUKOPENIA; LIVER FUNCTION TEST; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PANCYTOPENIA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCREENING; STEATOSIS; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOLUME OF DISTRIBUTION AT STEADY-STATE; CLINICAL TRIAL; PATHOLOGY; SAFETY; TREATMENT OUTCOME;

ADULT; AGED; BIOSIMILAR PHARMACEUTICALS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; RITUXIMAB; SAFETY; TREATMENT OUTCOME;

EID: 85023743077     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(17)30139-4     Document Type: Erratum

References (28)

1. European Medicines Agency. MabThera (rituximab) Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000165/WC500025821.pdf, 2015 (accessed Feb 26, 2017).
2. Marcus, R, Imrie, K, Belch, A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105 (2005), 1417–1423.
3. Salles, G, Seymour, JF, Offner, F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377 (2011), 42–51.
4. van Oers, MH, Klasa, R, Marcus, RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 108 (2006), 3295–3301.
5. Hiddemann, W, Kneba, M, Dreyling, M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106 (2005), 3725–3732.
6. National Comprehensive Cancer Network. B-cell Lymphomas. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf, 2017 (accessed June 14, 2017).
7. Eichhorst, B, Robak, T, Montserrat, E, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26:suppl 5 (2015), v78–v84.
8. Yoo, DH, Suh, CH, Shim, SC, et al. A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 76 (2017), 566–570.
9. Suh, C-H, Kasay, AB, El-Khouri, EC, et al. Pharmacokinetics and safety of three formulations of rituximab (CT-P10, US-sourced innovator rituximab and EU-sourced innovator rituximab) in patients with rheumatoid arthritis: results from Phase 3 randomized controlled trial over 24 weeks. Arthritis Rheumatol, 68(suppl 10), 2016, 1634 (abstr).
10. Yoo, D-H, Majstorovic, LB, Kasay, AB, et al. Efficacy and safety of CT-P10, rituximab biosimilar candidate, and innovator rituximab in patients with rheumatoid arthritis: results from Phase 3 randomized controlled trial over 24 weeks [abstract]. Arthritis Rheumatol, 68(suppl 10), 2016, 1635 (abstr).
11. Food and Drugs Administration. Scientific considerations in demonstrating biosimilarity to a reference product: Guidance for industry. http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf, 2015 (accessed Dec 2, 2016).
12. Gulácsi, L, Brodszky, V, Baji, P, Rencz, F, Péntek, M, The rituximab biosimilar CT-P10 in rheumatology and cancer: A budget impact analysis in 28 European countries. Adv Ther 34 (2017), 1128–1144.
13. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf, 2014 (accessed Dec 2, 2016).
14. Swerdllow, S, Campo, E, Harris, NL, et al. (eds.) WHO classification of tumours of haematopoietic and lymphoid tissues, 2008, IARC Press, France.
15. Cheson, BD, Horning, SJ, Coiffier, B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol, 17, 1999, 1244.
16. Federico, M, Luminari, S, Dondi, A, et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol 31 (2013), 1506–1513.
17. Schuirmann, DJ, A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 15 (1987), 657–680.
18. EU Clinical Trials Register. Protocol BO22334 (A two-stage phase III, international, multicenter, randomized, controlled, open-label study to investigate the PK, efficacy and safety of rituximab SC in combination with CHOP or CVP versus rituximab IV in combination with CHOP or CVP in patients with previously untreated FL followed by maintenance treatment with either rituximab SC or rituximab IV) [SABINA study]. ClinicalTrials.gov identifier: NCT01200758. 2010. https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-021377-36/results (accessed Feb 13, 2017).
19. Golay, J, Semenzato, G, Rambaldi, A, et al. Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs 5 (2013), 826–837.
20. Berinstein, NL, Grillo-Lopez, AJ, White, CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 9 (1998), 995–1001.
21. Jager, U, Fridrik, M, Zeitlinger, M, et al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica 97 (2012), 1431–1438.
22. Piro, LD, White, CA, Grillo-Lopez, AJ, et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 10 (1999), 655–661.
23. Kitay-Cohen, Y, Lishner, M, Shelef, A, Ravid, M, Manor, Y, Bone marrow involvement, in intensively treated patients with intermediate grade non-Hodgkin's lymphoma, is a risk factor for granulocytopenia and fever. Leuk Lymphoma 20 (1996), 333–336.
24. Lyman, GH, Abella, E, Pettengell, R, Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. Crit Rev Oncol Hematol 90 (2014), 190–199.
25. National Institute for Health and Care Excellence. Non-Hodgkin's lymphoma: diagnosis and management. https://www.nice.org.uk/guidance/ng52/resources/nonhodgkins-lymphoma-diagnosis-and-management-pdf-1837509936325, 2016 (accessed June 14, 2017).
26. US Food and Drug Administration. Guidance for industry: Clinical trial endpoints for the approval of cancer drugs and biologics. https://www.fda.gov/downloads/Drugs/Guidances/ucm071590.pdf, 2007 (accessed June 14, 2017).
27. Jurczak, W, Ilidia, M, Govindbabu, KS, et al. A Phase III efficacy and safety study of the proposed rituximab biosimilar GP2013 versus rituximab in patients with previously untreated advanced follicular lymphoma. Blood, 128, 2016, 1809.
28. Cohen, S, Emery, P, Greenwald, M, et al. A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis. Br J Clin Pharmacol 82 (2016), 129–138.